Wet AMD biotech stock soars over 200% as lead as­set match­es Re­gen­eron’s Eylea in PhII test

Eye­Point Phar­ma­ceu­ti­cals’ wet age-re­lat­ed mac­u­lar de­gen­er­a­tion (AMD) ther­a­py has demon­strat­ed non-in­fe­ri­or­i­ty to Re­gen­eron’s Eylea, even with a less fre­quent dos­ing reg­i­men in a mid-stage study, prompt­ing its share price to rock­et by more than 200% on Mon­day morn­ing.

The biotech’s share price $EYPT now sits at around $20, up from $6.61 at pre­vi­ous close. Pa­tients with wet AMD in the 56-week Phase II DAVIO 2 tri­al re­ceived a sin­gle in­jec­tion of ei­ther 2 mg or 3 mg of EYP-1901, or bi-month­ly in­jec­tions of Eylea. The tri­al en­rolled a to­tal of 160 sub­jects who were pre­vi­ous­ly dosed with at least two stan­dard of care an­ti-VEGF in­jec­tions in six months pri­or to screen­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER